abt-122 was highly effective, potentially superior to ada for high-level response in joints and skin
Published 6 years ago • 40 plays • Length 1:59Download video MP4
Download video MP3
Similar videos
-
2:00
abt-122 highly effective for psa
-
8:47
sramila aithal, md | neratinib and dose escalation | optimizing therapy for her2 disease
-
1:39
how long will amd treatment results last?
-
1:07
dr. paul emery acr17 - microarray expression pathways in baricitinib vs adalimumab treated ra
-
2:31
abatacept equaled adalimumab for rheumatoid arthritis
-
11:07
autoimmune blistering diseases [#davincicases dermatology case 2]
-
3:46
ask the expert: do low volume metastatic disease patients benefit from early docetaxal?
-
1:31
sy-1425 plus azacitidine in rara-positive newly-diagnosed aml
-
1:45
dr. sramila aithal describes the herceptin adjuvant (hera) trial for her2-positive breast cancer
-
1:22
surpass: evaluating the next-generation of spear t-cell therapy
-
3:41
long-term follow-up: aml17 trial of ato and atra vs the standard of care in apl
-
1:30
what is your expertise in amd treatment?
-
1:40
dr. brambilla shares long-term activa bioactive case
-
11:49
interim overall survival analysis of aphinity (big 4-11
-
2:21
what are some common questions about amd treatment?
-
1:22
how long does amd treatment take?
-
1:18
versiti's greg denomme | aabb annual meeting
-
0:26
aav2/5-gfaabc1d-egfpmito